Although more expensive, study says teaching hospitals save more lives. My personal take.






Perhaps not evident to many patients, there are two kinds of hospitals–teaching and nonteaching–and an intense debate about which is better. Teaching hospitals, affiliated with medical schools, are the training grounds… Read more »

Idorsia leaps 45% in market debut; Actelion spinoff looks like sure bet with J&J backing to boot. How to invest.






Idorsia Ltd. (Allschwil CHE), the research-based spin-out from Actelion following the latter’s $30 billion acquisition by Johnson & Johnson (New Brunswick NJ), which has now been completed, started trading on… Read more »

Merck’s Keytruda aces another cancer trial as results dazzle researchers






The News: Hot on the heels of the final presentation at ASCO’s 4-day conference in Chicago, a small, new study is causing jaws to drop after it found that a… Read more »

CDC weighs in with new Zika data, heightened warning about complacency






The News: Zika has gradually disappeared from the headlines, buried under the daily avalanche of news coming out of the nation’s capital and terror attacks in Europe. But on Thursday… Read more »

CAR-T Therapy: Personalized medicine with the promise of a cure; payers will decide who gets it






The News: Swiss drug giant Novartis AG has drawn widespread praise and a rising dose of controversy pertaining to its breakthrough CAR-T therapy CTL019. The medicine is under review to… Read more »

ASCO, aka The Oncology Super Bowl for Biotechs, sends stocks in every direction






Steve’s Take: As another jam-packed annual meeting of the American Society of Clinical Oncology in Chicago wrapped up on Tuesday (June 6, 2017), with some 38,000 oncologists gathering together at… Read more »

Tesaro says it’s for sale, but who can afford it






The News: Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street… Read more »

Universal health care: a “right” or “privilege.” Wrong question, or already settled?






Steve’s Take: Bloomberg’s Ramesh Ponnuru poses the question: “Is there a ‘right’ to healthcare? Our arguments about health policy frequently highlight the question.” He goes on to say that “as… Read more »

Zika: Forgotten, but not gone; Trump budget would slash funds aimed at safeguarding the public






The News: As the weather gradually gets warmer, and in some areas more humid, public health officials in the United States are quietly gearing up to combat the threat still… Read more »

What’s wrong with Novartis? Actually nothing.






The News: Novartis AG (Basel CHE) has been the subject of widespread and lingering chatter to the effect that its stature among the Big Pharma league players has diminished, and… Read more »